Charles Schwab
KPTI icon

Charles Schwab’s Karyopharm Therapeutics KPTI Stock Holding History

Charles Schwab’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$605K Buy
61,943
+48,514
+361% +$421K ﹤0.01% 3189
2026
Q1 		$74.8K Buy
+13,429
New +$102K ﹤0.01% 3406
2025
Q1 		– Sell
-3,412
Closed -$34.6K – 3499
2024
Q4 		$34.6K Buy
3,412
+12
+0.4% +$145 ﹤0.01% 3461
2024
Q3 		$42.3K Hold
3,400
– – ﹤0.01% 3428
2024
Q2 		$44.2K Sell
3,400
-17,261
-84% -$286K ﹤0.01% 3522
2024
Q1 		$468K Hold
20,661
– – ﹤0.01% 3054
2023
Q4 		$268K Buy
20,661
+3,400
+20% +$45.8K ﹤0.01% 3237
2023
Q3 		$347K Sell
17,261
-3,029
-15% -$68K ﹤0.01% 3184
2023
Q2 		$545K Buy
20,290
+5,443
+37% +$234K ﹤0.01% 3007
2023
Q1 		$866K Buy
14,847
+1,058
+8% +$52.2K ﹤0.01% 2782
2022
Q4 		$703K Buy
13,789
+422
+3% +$29.3K ﹤0.01% 2900
2022
Q3 		$1.09M Buy
13,367
+35
+0.3% +$2.61K ﹤0.01% 2762
2022
Q2 		$902K Buy
13,332
+386
+3% +$35.4K ﹤0.01% 2834
2022
Q1 		$1.43M Buy
12,946
+403
+3% +$50.2K ﹤0.01% 2742
2021
Q4 		$1.21M Hold
12,543
– – ﹤0.01% 2840
2021
Q3 		$1.1M Sell
12,543
-18,461
-60% -$1.92M ﹤0.01% 2841
2021
Q2 		$4.8M Buy
31,004
+854
+3% +$124K ﹤0.01% 2375
2021
Q1 		$4.76M Sell
30,150
-988
-3% -$208K ﹤0.01% 2326
2020
Q4 		$7.23M Sell
31,138
-3,256
-9% -$754K ﹤0.01% 2043
2020
Q3 		$7.53M Buy
34,394
+4,813
+16% +$1.18M ﹤0.01% 1861
2020
Q2 		$8.4M Buy
29,581
+3,838
+15% +$1.14M ﹤0.01% 1747
2020
Q1 		$7.42M Buy
25,743
+2,385
+10% +$658K ﹤0.01% 1627
2019
Q4 		$6.72M Buy
23,358
+427
+2% +$92.6K ﹤0.01% 1870
2019
Q3 		$3.31M Buy
22,931
+2,647
+13% +$359K ﹤0.01% 2178
2019
Q2 		$1.82M Buy
20,284
+3,349
+20% +$269K ﹤0.01% 2401
2019
Q1 		$1.48M Sell
16,935
-988
-6% -$110K ﹤0.01% 2448
2018
Q4 		$2.52M Sell
17,923
-210
-1% -$35.4K ﹤0.01% 2240
2018
Q3 		$4.63M Buy
18,133
+972
+6% +$269K ﹤0.01% 2092
2018
Q2 		$4.37M Buy
17,161
+5,948
+53% +$1.47M ﹤0.01% 2069
2018
Q1 		$2.26M Buy
11,213
+1,194
+12% +$238K ﹤0.01% 2285
2017
Q4 		$1.44M Buy
10,019
+662
+7% +$106K ﹤0.01% 2415
2017
Q3 		$1.54M Buy
9,357
+1,621
+21% +$232K ﹤0.01% 2371
2017
Q2 		$1.05M Buy
7,736
+1,968
+34% +$291K ﹤0.01% 2436
2017
Q1 		$1.11M Buy
5,768
+251
+5% +$40.3K ﹤0.01% 2391
2016
Q4 		$778K Buy
5,517
+1,293
+31% +$175K ﹤0.01% 2501
2016
Q3 		$617K Buy
4,224
+191
+5% +$23K ﹤0.01% 2551
2016
Q2 		$406K Buy
4,033
+59
+1% +$7.67K ﹤0.01% 2667
2016
Q1 		$532K Buy
3,974
+71
+2% +$7.84K ﹤0.01% 2555
2015
Q4 		$776K Buy
3,903
+91
+2% +$19.7K ﹤0.01% 2475
2015
Q3 		$603K Sell
3,812
-246
-6% -$65.8K ﹤0.01% 2550
2015
Q2 		$1.66M Buy
4,058
+782
+24% +$338K ﹤0.01% 2185
2015
Q1 		$1.5M Buy
3,276
+1,211
+59% +$522K ﹤0.01% 2211
2014
Q4 		$1.16M Buy
2,065
+21
+1% +$11.9K ﹤0.01% 2287
2014
Q3 		$1.07M Buy
2,044
+446
+28% +$252K ﹤0.01% 2263
2014
Q2 		$1.12M Buy
1,598
+452
+39% +$210K ﹤0.01% 2267
2014
Q1 		$531K Buy
1,146
+28
+3% +$14.2K ﹤0.01% 2565
2013
Q4 		$385K Buy
+1,118
New +$309K ﹤0.01% 2687

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Charles Schwab's KPTI Position: Q2 2026 in Review

Charles Schwab increased its Karyopharm Therapeutics (KPTI) stake by 361% in Q2 2026, buying an estimated $421K and bringing the position to 61,943 shares worth $605K. The position accounts for ﹤0.01% of the portfolio, ranked #3189.

Charles Schwab first reported a position in KPTI in Q4 2013 and has held it in 47 quarters since. The position peaked at $8.4M in Q2 2020. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Charles Schwab held 61,943 shares of Karyopharm Therapeutics worth $605K as of Q2 2026.
  • Charles Schwab bought 48,514 Karyopharm Therapeutics shares in Q2 2026, an estimated $421K.
  • Karyopharm Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3189 holding.
  • Charles Schwab first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 47 quarters since.
  • Charles Schwab's Karyopharm Therapeutics position peaked at $8.4M in Q2 2020.
  • 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.